UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) January 4, 2012
SALIX PHARMACEUTICALS, LTD.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
000-23265 | 94-3267443 | |
(Commission File Number) |
(IRS Employer ID Number) |
8510 Colonnade Center Drive, Raleigh, North Carolina 27615
(Address of principal executive offices) (Zip Code)
Registrants telephone number, including area code (919) 862-1000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01. | Other Events. |
On January 4, 2012, Salix issued a press release announcing that the Company will present at The 30th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 11, 2012 at 4:30 p.m. PT (7:30 p.m. ET). A copy of this press release is attached as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits.
(d) | Exhibits |
Exhibit |
Description | |
99.1 | Press release dated January 4, 2012. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.
SALIX PHARMACEUTICALS, LTD. | ||
Date: January 5, 2012 | ||
/s/ Adam C. Derbyshire | ||
Adam C. Derbyshire | ||
Executive Vice President and Chief Financial Officer |
Exhibit 99.1
FOR IMMEDIATE RELEASE
Contact: | ||||
Adam C. Derbyshire | G. Michael Freeman | |||
Executive Vice President | Associate Vice President, Investor Relations | |||
and Chief Financial Officer | and Corporate Communications | |||
919-862-1000 | 919-862-1000 |
SALIX PHARMACEUTICALS TO PRESENT AT
J.P. MORGAN HEALTHCARE CONFERENCE
RALEIGH, NC, January 4, 2012 - Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will present at The 30th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 11, 2012 at 4:30 p.m. PT (7:30 p.m. ET).
Interested parties can access a live audio web cast of the presentation at http://www.salix.com. A replay of the presentation will be available at the same location.
Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North Carolina, develops and markets prescription pharmaceutical products for the treatment of gastrointestinal diseases. Salixs strategy is to in-license late-stage or marketed proprietary therapeutic drugs, complete any required development and regulatory submission of these products, and market them through the Companys gastroenterology specialty sales and marketing team.
Salix trades on the NASDAQ Global Select Market under the ticker symbol SLXP.
For more information, please visit our Website at www.salix.com or contact the Company at 919-862-1000. Follow us on Twitter (@SalixPharma) and Facebook (www.facebook.com/SalixPharma). Information on our web site is not incorporated in our SEC filings.